Research
Hormonal
Liraglutide 3.0 mg administered subcutaneously once daily produces significant but numerically lower weight loss compared to semaglutide and is less cost-effective, though it remains a safe and efficacious option for obesity management.
Liraglutide 3.0mg once daily is an effective treatment for obesity, producing an average 5.6kg weight loss. It is less effective than semaglutide and tirzepatide. It remains a safe option, particularly for those who may not respond as well to other agents or have specific contraindications.
GoodQualifiesHIGH confidence
treatment with liraglutide 3.0 mg... was shown to result in a significant reduction in body weight by 5.6 kg versus placebo... weight-lowering effects of liraglutide among individuals with obesity, which are, however, numerically lower compared to that observed with semaglutide... liraglutide is substantially less cost-effective versus semaglutide for the therapeutic management of obesity.
Why this rating
Supported by RCTs (SCALE) and real-world studies.
Source
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias et al. · Pragmatic and Observational Research · 2024
DOI 10.2147/por.s471476
narrative_reviewCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg administered subcutaneously once-weekly produces significant body weight reduction (mean 12.2 kg or 11.8%) and improves cardiometabolic parameters in adults with obesity, with real-world evidence confirming efficacy similar to randomized controlled trials.Good
- Tirzepatide, a dual GLP-1/GIP receptor agonist, produces significantly greater body weight reduction (up to 20.9% at 15mg) compared to semaglutide and other GLP-1 agonists in patients with obesity, with real-world studies confirming superior efficacy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →